Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Gossamer Bio Inc.
Headquarters: San Diego, CA, United States of America
Website: http://gossamerbio.com
Year Founded: 2015
Status: Public
Industry Sector: HealthTechnology
CEO: Faheem Hasnain
Number Of Employees: 135
Enterprise Value: $55,306,273
PE Ratio: -3.95
Exchange/Ticker 1: NASDAQ:GOSS
Exchange/Ticker 2: N/A
Latest Market Cap: $294,585,216
BioCentury | May 7, 2024
Deals
Deals report: Novartis strengthens radiotherapy pipeline with pair of deals
Plus: Xyphos-Poseida to develop allogeneic CAR T therapies, Chiesi gains ex-U.S. right to Gossamer’s seralutinib, and more
BioCentury | Dec 6, 2023
Management Tracks
Catalyst hires Michael Kalb as CFO
Plus: Raab to become Amicus chair when Crowley heads to BIO and updates from AC Immune, Gossamer Bio, Chimerix, Versameb, Alzheon, Kling and Avalere
BioCentury | Sep 22, 2023
Politics, Policy & Law
IPO, M&A delays and more: How government shutdown will affect biopharma
FDA will review pending applications, won’t accept new NDAs, BLAs, SEC will not review IPOs
BioCentury | Sep 14, 2023
Management Tracks
Gilead hires a new general manager for Korea
Plus: Character Biosciences hires Gossamer alum Laura Carter as CSO and updates from Hookipa, hC, TCB, LifeSci Partners, Evecxia
BioCentury | Jul 21, 2023
Deals
July 20 Quick Takes: Via its second preclinical deal this week, Sanofi gains Recludix’s oral STAT6 inhibitor
Plus: Idorsia sells Japan, Korea business to Sosei and updates from Gossamer and BioNTech-Biotheus
BioCentury | Apr 4, 2023
Deals
April 4 Quick Takes: Scorpion, Pierre Fabre enter deal for pair of EGFRs
Plus: EUA for InflaRx’s antibody for COVID-19 and updates from Adcendo, Mercy, Mosaic, Freeline and Gossamer
BioCentury | Apr 4, 2023
Finance
Newly launched Cure Ventures taking hands-on approach to company creation
Three co-founders with experience at other firms hope to seed about 20 companies with $350M first fund
BioCentury | Mar 18, 2023
Finance
March 17 Quick Takes: Digital play Pear seeking alternatives
Plus: Gossamer pauses brain-penetrant Btk program, and updates from Pfizer, Astellas, Novartis and more
BioCentury | Jan 12, 2023
Finance
Get used to markets with no nuance, says Blackstone’s Kiran Reddy
2023 will be a year to digest the upheaval of 2022, and the bar for catalysts has been raised: Reddy on The BioCentury Show
BioCentury | Dec 7, 2022
Product Development
Dec. 6 Quick Takes: Gossamer falls on PAH data
Plus: HotSpot, AbbVie in IRF5 collaboration and updates from Leo, MorphoSys-Novartis, Pfizer-Clear Creek
Items per page:
1 - 10 of 58